
This phase 1 study evaluated the safety, zzso and activity of zzso a fully human, zzso zzso zzso that targets the zzso growth factor zzso in patients with previously treated zzso growth factor zzso advanced solid zzso 

zzso zzso were enrolled to receive four zzso infusions of zzso zzso at various doses and zzso Safety was continuously zzso zzso samples for zzso zzso and chemistry assessments were drawn at zzso zzso zzso response was assessed at week zzso 

zzso patients received zzso Median zzso age was 61 years zzso zzso and 72 zzso patients were zzso zzso types were zzso zzso cancer, zzso zzso zzso zzso zzso zzso cell zzso zzso zzso zzso zzso and zzso zzso The overall zzso of grade 3 or 4 adverse events was zzso and zzso zzso The zzso of zzso zzso was dose zzso No maximum tolerated dose was zzso No human zzso zzso were zzso No zzso zzso zzso reactions were zzso zzso zzso zzso were similar in the zzso zzso weekly, zzso zzso every 2 weeks, and zzso zzso every 3 weeks dose zzso Five of 39 patients zzso with zzso cancer had a confirmed partial response, and 9 of 39 patients zzso with zzso cancer had stable zzso 

zzso was well tolerated with comparable exposure and safety profiles for the weekly, every 2 weeks, and every 3 weeks administration zzso zzso and dry skin occurred more frequently in the dose zzso receiving zzso or zzso zzso weekly zzso zzso has zzso zzso activity, most notably in patients with advanced zzso zzso 

